<DOC>
	<DOCNO>NCT00523224</DOCNO>
	<brief_summary>Study title : A Study Combined Coronary Artery Bypass Grafting ( CABG ) Blood-Borne Autologous Angiogenic Cell Precursors Therapy Patients Congestive Heart Failure due Ischemic Heart Disease ( ACPs-CHF ) Principle Investigator : Kit V. Arom , M.D. , Ph.D . Deputy Director , Chief Cardio-Thoracic Surgeon , Bangkok Heart Hospital Study objective : To determine safety efficacy injection blood-borne autologous ACPs non-graftable area heart patient congestive heart failure due ischemic heart disease Its main goal evaluation feasibility safety combine technique . The efficacy treatment test follow trial . Study Design : Phase I , single center , non-randomized , open-label trial test safety , intramyocardium transepicardium administration ex vivo expand autologous ACPs administer combination CABG operation patient congestive heart failure due ischemic heart disease . The study preliminary training study , supervision experience Dr. Patel U.S. principal investigator . Study population : Total expect . patient : 5 main selection criterion : 1 . Patients without sign congestive heart failure due ischemic heart disease maximal medical treatment . Not suitable percutaneous intervention 2 . All patient must recent coronary angiogram . Patients must able OPCAB Angiogenic Cell Precursors ( ACPs ) non-graftable and/or infraction region 3 . Age 18 80 year 4 . MRI demonstrate area viable non-viable myocardium Investigational Product : The patient blood drawn 250 ml D-8 producting autologous ACPs ( VescellTM ) , On D0 , least 1.5 million ACPs viability &gt; 75 % supended 15 ml sterile cell culture medium inject 1 cm apart use 23 gauge angle needle 30 spot ( 0.5 ml /point ) patient direct intramuscular approach LV CABG . The study consist 4 period : Screening ( D-14 to-9 &amp; D-8 , Treatment ( D0 ) , Acute Safety follow-up ( D1-2 &amp; D5-discharge ) , Chronic follow-up ( D30 &amp; D90 ) period , total follow-up case 3 month . Evaluation criterion : Safety : no. &amp; duration adverse event &amp; serious adverse event Efficacy : NYHA , 6-minute walk test , % LVEF Echocardiography &amp; C-MRI , % infracted scar area C-MRI , Pro-BNP &amp; 3 month QoL ( SF-36 )</brief_summary>
	<brief_title>ACPs Combined With CABG Patients With CHF</brief_title>
	<detailed_description>Five CAD patient require CABG without congestive heart failure undergo screen receive ACPs 's injection direct intramuscular CABG operation . After , patient come follow investigator 1 3 month post surgery order evaluate safety efficacy stem cell therapy ( ACPs ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patients without sign congestive heart failure due ischemic heart disease maximal medical treatment . Not suitable percutaneous intervention 2 . All patient must recent coronary angiogram . Patients must able OPCAB Angiogenic Cell Precursors ( ACPs ) nongraftable and/or infraction region 3 . Age 18 80 year 4 . Male nonpregnant , nonlactating female 5 . MRI demonstrate area viable nonviable myocardium 6 . Informed consent obtain consent form sign 1 . Prior Cardiac Surgery Heart Transplantation 2 . Patient receive blood transfusion previous 4 week ( exclude potential nonautologous ACPs harvest blood ) . 3 . Inability communicate ( may interfere clinical evaluation patient ) 4 . Acute Myocardial infarction &lt; 6 day acute event 5 . Significant valvular disease valve replacement 6 . Left Ventricular Aneurysm 7 . Collagen tissue disease 8 . History Prior Radiation Exposure 9 . History alcohol drug abuse within 3 month screen 10 . Renal failure ( creatinine &gt; 2 mg/dl ) Hemodialysis 11 . Hepatic failure History Liver Cirrhosis 12 . Females capable reproduction take acceptable measure prevent reproduction study . 13 . Anemia ( low 11mg/dl.hemoglobin female low 12 mg/dl male ) 14 . Abnormal coagulation test normal [ platelet , PT ( INR ) , PTT ] 15 . Stroke within precede 3 year 16 . Malignancy within precede 3 year 17 . Concurrent chronic acute infectious disease 18 . Severe concurrent medical disease ( e.g. , septicemia , HIV1,2/HBV/HCV infection , insulindependent diabetes mellitus , systemic lupus erythematosus , multiple sclerosis , amyotrophic lateral sclerosis ) 19 . Chronic immunomodulating cytotoxic drug treatment 20 . Patients rectal temp . 38.40C 2 consecutive day 21 . Patient unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>Coronary Artery Bypass grafting</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Angiogenesis</keyword>
</DOC>